Eli Lilly & Co., a global pharmaceutical company, will add about 50 new jobs and expand its biotech center in New York City, the company announced in a press release.
The Indiana-based company said its plans to add 30,000 square feet of office space at the Alexandria Center for Life Science, a research and development site at 430 East 29th Street, The Wall Street Journal first reported. Eli Lilly has occupied 90,000 square feet since it moved into the space in 2010, according to the company.
Set to be complete in 2016, the expansion will provide space for immune system research and cancer treatment, as well as strengthen access for local academic scientists, according to the release. The firm declined to provide the asking rent, the length of the lease and the brokers involved in the deal.
“Our expanded capabilities at the New York site will further [Eli] Lilly’s expertise in our core therapeutic areas and help pave the way for broader collaboration with leading academic, health care and industry colleagues,” said Jan Lundberg, executive vice president of science and technology and president of Lilly Research Laboratories, said in prepared remarks.
Eli Lilly’s been ramping up its research and development facilities this year in other biotech hubs. That includes building an innovation center in Cambridge, Mass. in May, and expanding its biotech center in San Diego, Calif. in July.
The Alexandria Center for Life Science houses other pharmaceutical giants and technology companies, such as Pfizer, Roche Holding AG and New York University Neuroscience Institute. The two-tower science campus sits between East 28th and East 30th Streets.